Radiopharm Theranostics is a clinical-stage biotechnology company developing first-in-class radiopharmaceuticals for oncology targets. The company utilizes proprietary platforms including nanobodies, antibodies, small molecules, and peptides for precision targeting in radiotherapeutics and radiodiagnostics. Their focus is on advancing novel agents to address significant unmet needs in cancer care.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of effective cancer therapies is hindered by the need for targeted delivery mechanisms that can precisely reach tumor cells while minimizing off-target effects. Traditional treatments often lack the specificity required to address the complex heterogeneity of cancer, leading to suboptimal therapeutic outcomes and increased toxicity.
Solution
Radiopharm Theranostics is a clinical-stage biotechnology company focused on developing first-in-class radiopharmaceuticals for oncology. The company leverages proprietary platforms, including nanobodies, antibodies, small molecules, and peptides, to create targeted therapies and diagnostics. By focusing on novel oncology pathways and avoiding commonly targeted antigens, Radiopharm aims to address significant unmet needs in cancer care. Their approach integrates advanced molecular targeting with radioisotope delivery to enhance therapeutic efficacy and diagnostic precision.
Target Audience
The primary target audience includes oncologists, nuclear medicine physicians, and researchers involved in cancer therapy and diagnostics.
Features
- Development of radiopharmaceutical candidates utilizing nanobody, antibody, small molecule, and peptide targeting modalities.
- Focus on novel oncology targets, specifically excluding commonly targeted antigens such as PSMA, FAP, and SSTR2.
- Pipeline includes therapeutic agents utilizing isotopes such as Lutetium-177 (Lu177) and Terbium-161 (Tb161).
- Diagnostic imaging agents are being developed using isotopes like Fluorine-18 (F18) and Gallium-68 (Ga68).
- Clinical-stage programs include Phase I and Phase II trials for various solid tumor indications.
- Specific therapeutic programs target PD-L1 (RAD204), HER2 (RAD202), and B7-H3 (RV01/Betabart).
- Diagnostic programs include FASN targeting for brain metastases (RAD101) and integrin αVβ6 targeting (RAD301).
- Preclinical programs include KLK3 targeting for prostate cancer (RAD402) and integrin αVβ6 targeting for solid tumors (RAD302).
- Strategic collaborations, including a joint venture with MD Anderson Cancer Center, support pipeline advancement.